XML 40 R21.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment Reporting and Foreign Operations | 12 Months Ended
--- | ---
Dec. 31, 2018
Segment Reporting [Abstract] |
Segment Reporting and Foreign Operations | SEGMENT REPORTING AND FOREIGN OPERATIONS We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of cardiology and radiology medical device products which assist in diagnosing and treating coronary artery disease, peripheral vascular disease and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management ("CRM"), electrophysiology ("EP"), critical care, Cianna Medical, interventional oncology and spine devices, and breast cancer localization and guidance. Our endoscopy segment consists of gastroenterology and pulmonology medical device products which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. We evaluate the performance of our operating segments based on operating income (loss). See Note 2 for a detailed breakout of our sales by operating segment and product group, disaggregated between domestic and international sales. During the years ended December 31, 2018, 2017 and 2016, we had international sales of approximately $386.3 million, $307.1 million and $233.5 million, respectively, or approximately 44%, 42% and 39%, respectively, of net sales, primarily in China, Japan, Germany, France, the United Kingdom and Russia. China represents our most significant international sales market with sales of approximately $92.7 million, $73.4 million, and $59.9 million for the years ended December 31, 2018, 2017 and 2016, respectively. International sales are attributed based on location of the customer receiving the product. Our long-lived assets (which are comprised of our net property, plant and equipment) by geographic area at December 31, 2018, 2017 and 2016, consisted of the following (in thousands):
| 2018 |  | 2017 |  | 2016
United States | $ | 231,864 |  |  | $ | 202,504 |  |  | $ | 194,715 |
Ireland | 45,283 |  |  | 45,671 |  |  | 47,337 |
Other foreign countries | 54,305 |  |  | 44,645 |  |  | 34,521 |
Total | $ | 331,452 |  |  | $ | 292,820 |  |  | $ | 276,573 |
Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the years ended December 31, 2018, 2017 and 2016, are as follows (in thousands):
| 2018 |  | 2017 |  | 2016
Net Sales |  |  |  |  |  |  |  |
Cardiovascular | $ | 849,477 |  |  | $ | 700,613 |  |  | $ | 580,151 |
Endoscopy | 33,276 |  |  | 27,239 |  |  | 23,687 |
Total net sales | 882,753 |  |  | 727,852 |  |  | 603,838 |
Operating expenses |  |  |  |  |  |  |  |
Cardiovascular | 321,461 |  |  | 281,095 |  |  | 218,659 |
Endoscopy | 14,692 |  |  | 12,089 |  |  | 11,490 |
Total operating expenses | 336,153 |  |  | 293,184 |  |  | 230,149 |
Operating income |  |  |  |  |  |  |  |
Cardiovascular | 49,289 |  |  | 24,819 |  |  | 30,053 |
Endoscopy | 9,328 |  |  | 8,250 |  |  | 4,823 |
Total operating income | 58,617 |  |  | 33,069 |  |  | 34,876 |
Total other income (expense) - net | (9,098 | ) |  | 2,812 |  |  | (9,490 | )
Income tax expense | 7,502 |  |  | 8,358 |  |  | 5,265 |
Net income | $ | 42,017 |  |  | $ | 27,523 |  |  | $ | 20,121 |
Total assets by business segment at December 31, 2018, 2017 and 2016, consisted of the following (in thousands):
| 2018 |  | 2017 |  | 2016
Cardiovascular | $ | 1,588,970 |  |  | $ | 1,103,806 |  |  | $ | 932,927 |
Endoscopy | 31,042 |  |  | 8,005 |  |  | 9,876 |
Total | $ | 1,620,012 |  |  | $ | 1,111,811 |  |  | $ | 942,803 |
Total depreciation and amortization by business segment for the years ended December 31, 2018, 2017, and 2016 consisted of the following (in thousands):
| 2018 |  | 2017 |  | 2016
Cardiovascular | $ | 68,722 |  |  | $ | 52,700 |  |  | $ | 42,806 |
Endoscopy | 824 |  |  | 882 |  |  | 949 |
Total | $ | 69,546 |  |  | $ | 53,582 |  |  | $ | 43,755 |
Total capital expenditures for property and equipment by business segment for the years ended December 31, 2018, 2017 and 2016 consisted of the following (in thousands):
| 2018 |  | 2017 |  | 2016
Cardiovascular | $ | 63,032 |  |  | $ | 38,437 |  |  | $ | 32,613 |
Endoscopy | 292 |  |  | 186 |  |  | 224 |
Total | $ | 63,324 |  |  | $ | 38,623 |  |  | $ | 32,837 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration